Rezolute Inc.

AI Score

0

Unlock

4.69
-0.06 (-1.26%)
At close: Jan 14, 2025, 3:59 PM
4.72
0.64%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 4.58
Market Cap 271.75M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.27
PE Ratio (ttm) -3.69
Forward PE n/a
Analyst Buy
Ask 4.94
Volume 388,601
Avg. Volume (20D) 403,501
Open 4.83
Previous Close 4.75
Day's Range 4.69 - 4.98
52-Week Range 0.90 - 6.19
Beta undefined

About RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2013
Employees 59
Stock Exchange NASDAQ
Ticker Symbol RZLT

Analyst Forecast

According to 8 analyst ratings, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 145.20% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
4 months ago · Source
+22.07%
Rezolute shares are trading higher after the compa... Unlock content with Pro Subscription
7 months ago · Source
-23.45%
Rezolute shares are trading lower after the company announced a proposed public offering of common stock and pre-funded warrants.